CITCCA data demonstrate more than 40% of high-risk stage I–III colorectal patients harbor molecular residual disease at clinical landmark, detectable only with ultrasensitive ctDNA testingMORRISVILLE, ...
KNOXVILLE, TN, UNITED STATES, January 8, 2026 /EINPresswire.com/ -- Daisy Genomics Inc. (“Daisy Genomics”) and New Day ...
New global initiative urges patients and clinicians to wait for biomarker testing results before starting treatment.
A blood-based colorectal cancer (CRC) screening test, SimpleScreen™, has shown a significant leap in performance, ...
There is no increased risk for colorectal cancer, advanced-stage cancer, or advanced adenoma when colonoscopy is delayed up to 24 months after a positive FIT result.
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield blood test for ...
A look at Exact Sciences Corporation’s acquisition by Abbott: review EXAS revenue growth, margins, and CRC/MRD screening ...
A blood-based liquid biopsy test detects early-onset colorectal cancer with strong diagnostic performance and high ...
In adjusted models, no significant differences were seen in colorectal cancer testing by social needs status. HealthDay News — Among adults aged 45 to 49 years who are newly eligible for colorectal ...
Get the latest news, expert insights, exclusive resources, and strategies from industry leaders – all for free.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback